Lgenia Joins TB Drug Accelerator Collaboration
Lgenia and Harvard join Gates Foundation’s TB Accelerator team
At the spring 2018 meeting of the Bill and Melinda Gates Foundation’s TB Drug Accelerator, two new institutions were elected as full member collaborators – Harvard University and LGENIA! We now join 20 other member organizations in this important mission, and we are proud to be the first biotechnology company on their team.
This collaboration brings together world-class expertise and resources to accelerate the discovery of new treatments for tuberculosis, a disease that remains the leading cause of death from infectious disease worldwide. By joining forces with the Gates Foundation and other global leaders, Lgenia is committed to driving innovation and making affordable, effective TB therapies accessible to all who need them.
- 20+ member organizations collaborating globally
- First biotechnology company to join the TB Drug Accelerator
- Focus: Accelerating drug discovery, improving patient access, and reducing treatment time
- Impact: Addressing multidrug-resistant TB and improving outcomes for vulnerable populations
“We are honored to join the TB Drug Accelerator and work alongside Harvard and other leading institutions. Together, we can make a real difference in the fight against tuberculosis.”
Learn more about the TB Drug Accelerator and our ongoing research at Lgenia.